PALB2 and breast cancer: Prior studies determined that combinations of mutation, copy loss, or epigenetic silencing resulting in biallelic loss of BRCA1, BRCA2, PALB2, or RAD51C in breast cancers associate with signatures of HRRd, predominantly CSig3 (19, 20).